Wexford Capital’s Akebia Therapeutics AKBA Stock Holding History

Wexford Capital’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-13,560	Closed	-$38K	–	196
2020 Q4	$38K	Buy	+13,560	New	+$39.6K	0.01%	271

Other funds holding AKBA

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital's AKBA Position: Q1 2021 in Review

Wexford Capital sold out of Akebia Therapeutics (AKBA) in Q1 2021, closing a stake of 13,560 shares — an estimated $38K sold.

Wexford Capital first reported a position in AKBA in Q4 2020 and held it in 1 quarter. The position peaked at $38K in Q4 2020. 145 funds tracked by Wall St. Rank hold AKBA as of Q1 2021.

Wexford Capital reported no remaining Akebia Therapeutics position as of Q1 2021 after selling out during the quarter.
Wexford Capital sold 13,560 Akebia Therapeutics shares in Q1 2021, an estimated $38K.
Wexford Capital first reported a position in Akebia Therapeutics in Q4 2020 and held it in 1 quarter.
Wexford Capital's Akebia Therapeutics position peaked at $38K in Q4 2020.
145 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.